About 1,380,000 results
Open links in new tab
  1. A Medicine Company | Eli Lilly and Company

    Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.

  2. Eli Lilly and Company - Wikipedia

    Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries.

  3. Lilly to Acquire Adverum Biotechnologies - PR Newswire

    4 days ago · Lilly is a medicine company turning science into healing to make life better for people around the world.

  4. Eli Lilly and Co. | Pharmaceuticals, Biomedical Research ...

    Lilly was founded in 1876 and became a publicly traded company in 1952. As of 2023, the Indianapolis-based company employs more than 42,900 employees worldwide.

  5. Find Your Career with Eli Lilly | Lilly Careers

    Find your place at Lilly with Lilly Careers. For more than a century, we have united caring with discovery to make life better, join us today.

  6. Eli Lilly to Buy Eye Gene Therapy Company Adverum ...

    4 days ago · Eli Lilly & Co. agreed to buy Adverum Biotechnologies Inc., a company working to treat blindness, in a deal that ultimately could be worth $261.7 million as it continues a push …

  7. Eli Lilly obesity pill beats Novo Nordisk drug in diabetes trial

    Sep 17, 2025 · Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk's oral semaglutide, and helped patients lose more weight.

  8. Lilly Dives Deeper Into Gene Therapy With up to ... - BioSpace

    4 days ago · The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet age-related macular degeneration. Eli Lilly made another foray …

  9. About Us | Eli Lilly and Company

    Key facts about Lilly Learn more about Lilly and our global presence at a glance.

  10. Lilly oncology head weighs in on FDA cancer drug policies

    Oct 21, 2025 · Lilly’s oncology chief, Jake Van Naarden, suggested that the FDA's policies on clinical trial crossover and high U.S. enrollment are not compatible.